Sodium–Glucose Cotransporter-2 Inhibitors and the Risk for Severe Urinary Tract Infections: A Population-Based Cohort Study
Open accessThe DOI matches its Crossref record; 7 of the 7 references it cites were found in a registry or an index.
Abstract
Background: Prior studies evaluating risk for severe urinary tract infections (UTIs) with sodium-glucose cotransporter-2 (SGLT-2) inhibitors have reported conflicting findings. Objective: To assess whether patients initiating use of SGLT-2 inhibitors were at increased risk for severe UTI events compared with those initiating use of dipeptidyl peptidase-4 (DPP-4) inhibitors or glucagon-like peptide-1 receptor (GLP-1) agonists. Design: Population-based cohort study. Setting: 2 large, U.S.-based databases of commercial claims (March 2013 to September 2015). Participants: Within each database, 2 cohorts were created and matched 1:1 on propensity score. Patients were aged 18 years or older, had type 2 diabetes mellitus, and were initiating use of SGLT-2 inhibitors versus DPP-4 inhibitors (cohort 1) or GLP-1 agonists (cohort 2). Measurements: The primary outcome was a severe UTI event, defined as a hospitalization for primary UTI, sepsis with UTI, or pyelonephritis; the secondary outcome was outpatient UTI treated with antibiotics. Hazard ratios (HRs) were estimated in each propensity score-matched cohort, with adjustment for more than 90 baseline characteristics. Results: After 1:1 matching on propensity score, 123 752 patients were identified in cohort 1 and 111 978 in cohort 2 in the 2 databases. In cohort 1, persons newly receiving SGLT-2 inhibitors had 61 severe UTI events (incidence rate [IR] per 1000 person-years, 1.76), compared with 57 events in the DPP-4 inhibitor group (IR, 1.77) (HR, 0.98 [95% CI, 0.68 to 1.41]). In cohort 2, those receiving SGLT-2 inhibitors had 73 events (IR, 2.15), compared with 87 events in the GLP-1 agonist group (IR, 2.96) (HR, 0.72 [CI, 0.53 to 0.99]). Findings were robust across sensitivity analyses; within several subgroups of age, sex, and frailty; and for canagliflozin and dapagliflozin individually. In addition, SGLT-2 inhibitors were not associated with increased risk for outpatient UTIs (cohort 1: HR, 0.96 [CI, 0.89 to 1.04]; cohort 2: HR, 0.91 [CI, 0.84 to 0.99]). Limitation: Generalizability of the study findings may be limited to patients with commercial insurance. Conclusion: In a large cohort of patients seen in routine clinical practice, risk for severe and nonsevere UTI events among those initiating SGLT-2 inhibitor therapy was similar to that among patients initiating treatment with other second-line antidiabetic medications. Primary Funding Source: Brigham and Women's Hospital, Division of Pharmacoepidemiology and Pharmacoeconomics.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Austin, P. C. (2011) · Multivariate Behavioral Research · doi:10.1080/00273171.2011.568786 · Cited by 12,242 · cited 1×
“groups (18) and examined the c-statistic for the logistic regression model (values closer to 0.”
Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes
Neal, B., Perkovic, V., Mahaffey, K. W., de Zeeuw, D., Fulcher, G., Erondu, N., Shaw, W., Law, G., Desai, M., & Matthews, D. R. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1611925 · Cited by 7,830
A basic introduction to fixed-effect and random-effects models for meta-analysis
Borenstein, M., Hedges, L. V., Higgins, J. P. T., & Rothstein, H. R. (2010) · Research Synthesis Methods · doi:10.1002/jrsm.12 · Cited by 6,793 · cited 1×
“Analyses were done in each database, and estimates were pooled through inverse-variance fixed-effects meta-analysis (20).”
Empagliflozin and Progression of Kidney Disease in Type 2 Diabetes
Wanner, C., Inzucchi, S. E., Lachin, J. M., Fitchett, D., von Eynatten, M., Mattheus, M., Johansen, O. E., Woerle, H. J., Broedl, U. C., & Zinman, B. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1515920 · Cited by 3,655
Sodium–Glucose Cotransporter 2 Inhibitors for Type 2 Diabetes: A Systematic Review and Meta-analysis
Vasilakou, D., Karagiannis, T., Athanasiadou, E., Mainou, M., Liakos, A., Bekiari, E., Sarigianni, M., Matthews, D. R., & Tsapas, A. (2013) · Annals of Internal Medicine · doi:10.7326/0003-4819-159-4-201308200-00007 · Cited by 911
Kosiborod, M., Cavender, M. A., Fu, A. Z., Wilding, J. P., Khunti, K., Holl, R. W., Norhammar, A., Birkeland, K. I., Jørgensen, M. E., Thuresson, M., et al. (2017) · Circulation · doi:10.1161/circulationaha.117.029190 · Cited by 813
Kim, D. H., Glynn, R. J., Avorn, J., Lipsitz, L. A., Rockwood, K., Pawar, A., & Schneeweiss, S. (2019) · The Journals of Gerontology: Series A · doi:10.1093/gerona/gly197 · Cited by 285
Self-citation
Research works printed but not linked: 20
- 10.1146/annurev-med-051013-110046 · DOI · Paper page
- 10.1136/bmj.k119 · DOI · Paper page
- 10.1099/00222615-48-6-535 · doi:10.1099/00222615-48-6-535
- 10.1016/S0924-8579(02)00090-0 · DOI
- 10.1111/dom.12825 · DOI · Paper page
- 10.1111/dom.13531 · DOI · Paper page
- 10.1007/s00592-018-1116-0 · DOI · Paper page
- 10.1016/S2213-8587(16)00052-8 · DOI · Paper page
- 10.1002/psb.1521 · DOI
- 10.1016/S0149-2918(98)80007-6 · DOI · Paper page
- 10.1093/gerona/glx229 · DOI · Paper page
- 10.1002/sim.6058 · DOI · Paper page
- 10.1002/pds.3263 · DOI · Paper page
- 10.1097/EDE.0000000000000595 · DOI · Paper page
- 10.1097/01.ju.0000155596.98780.82 · DOI · Paper page
- 10.1016/j.archger.2011.07.012 · DOI
- 10.1093/clinids/21.2.316 · DOI · Paper page
- 10.1016/S0924-8579(00)00356-3 · DOI
- 10.1016/j.diabres.2017.06.018 · DOI · Paper page
- 10.1111/dom.13184 · DOI · Paper page
Cited by
SGLT2 inhibitors and GLP-1 receptor agonists: established and emerging indications
Brown, E., Heerspink, H. J. L., Cuthbertson, D. J., & Wilding, J. P. H. (2021) · The Lancet · doi:10.1016/s0140-6736(21)00536-5 · Cited by 581
Sodium–glucose cotransporter type 2 inhibitors for the treatment of type 2 diabetes mellitus
Scheen, A. J. (2020) · Nature Reviews Endocrinology · doi:10.1038/s41574-020-0392-2 · Cited by 267
Rangaswami, J., Bhalla, V., de Boer, I. H., Staruschenko, A., Sharp, J. A., Singh, R. R., Lo, K. B., Tuttle, K., Vaduganathan, M., Ventura, H., et al. (2020) · Circulation · doi:10.1161/cir.0000000000000920 · Cited by 192
Sarafidis, P. A., & Ortiz, A. (2020) · Clinical Kidney Journal · doi:10.1093/ckj/sfz170 · Cited by 37
“[19] added a set of real-world data pointing in the same direction.”
BackgroundGonzalez, J., Bates, B. A., Setoguchi, S., Gerhard, T., & Dave, C. V. (2023) · Cardiovascular Diabetology · doi:10.1186/s12933-023-01784-w · Cited by 32
Self-citationCampesi, I., Seghieri, G., & Franconi, F. (2021) · Current Opinion in Pharmacology · doi:10.1016/j.coph.2021.06.007 · Cited by 25
Wang, E., Patorno, E., Khosrow-Khavar, F., Crystal, S., & Dave, C. V. (2025) · Diabetologia · doi:10.1007/s00125-024-06321-2 · Cited by 14
Self-citation
Metadata
- Authors
- Dave, C. V., Schneeweiss, S., Kim, D., Fralick, M., Tong, A., & Patorno, E.
- Venue
- Annals of Internal Medicine
- Publisher
- American College of Physicians
- Published
- 2019-08-20
- Volume
- 171
- Issue
- 4
- Pages
- 248-256
- ISSN
- 0003-4819 (ISSN-L)
- 1539-3704
- OpenAlex
- W2966426030
- Cited by
- 221
- References
- 7
- FWCI
- 14.24
- Type
- journal article
- Language
- en
- Open access
- green
- Licence
- www.acpjournals.org/journal/aim/text-and-data-mining (tdm)
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.